Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Recruiting · NCT06590428 · Interventional (participants receive a specific treatment) · Lead sponsor: Albert Einstein College of Medicine
View the official record on ClinicalTrials.gov →Interventions studied
Therapeutic Drug Monitoring for Linezolid
What this trial is about
This study is a two-arm, pragmatic, open-label, randomized clinical trial to determine the efficacy of Therapeutic Drug Monitoring (TDM) in preventing premature discontinuation of Linezolid (LZD) in participants with Rifampicin-resistant tuberculosis (RR-TB). Following the initiation of treatment, participants will be monitored throughout the approximate 6-month duration of RR-TB therapy.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adult male or female patient \> 18 years of age
- Microbiological confirmation of rifampicin-resistant tuberculosis (e.g., phenotypic or genotypic drug susceptibility testing, GeneXpert MTB/RIF™). Participants may have resistance to additional medications as well - i.e., MDR and XDR TB - but must have resistance to at least rifampin
- Initiated on a rifampicin-resistant tuberculosis (RR-TB) treatment regimen containing linezolid, no more than 14 days prior to randomization
- HIV status is known and confirmed
- Both HIV-positive and HIV-negative individuals are eligible
- If an individual reports unknown HIV status, they must consent to HIV testing at time of enrollment to confirm status. If they decline to be tested, they are not eligible for the study
Exclusion criteria
- Severe medical condition with expected death in the next 7 days
- Pregnant at time of screening
- Initial linezolid dose \< 600mg daily
- Severe form of extrapulmonary TB (i.e., meningitis, pericarditis, or osteomyelitis)
- Unlikely to follow-up at Nkqubela Hospital based on location of residence
Where it is running
1 location listed.
- Nkqubela TB Specialist Hospital - East London, Eastern Cape, South Africa